menu
    • menu

    Company profile for Menlo Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. We have completed four double‑blind Phase 2 clinical trials in more than 1,000 patients with pruritus and observed clinically relevant and statistically significant improvements in pruritus in patients treated with serlopitant compared to patien...
    Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. We have completed four double‑blind Phase 2 clinical trials in more than 1,000 patients with pruritus and observed clinically relevant and statistically significant improvements in pruritus in patients treated with serlopitant compared to patients treated with placebo in three of the four trials. Our clinical development program for serlopitant includes two ongoing Phase 3 clinical trials for the treatment of pruritus associated with prurigo nodularis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Menlo TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Cardinal Way, 2nd Floor Redwood City, CA 94063
    Telephone
    Telephone
    650-486-1416
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.menlotherapeutics.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/menlo-therapeutics-inc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Menlo Therapeutics Announces Pricing of Offering of Common Stock
    Menlo Therapeutics Announces Pricing of Offering of Common Stock

    05 Jun 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/06/05/2044238/0/en/Menlo-Therapeutics-Announces-Pricing-of-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    05 Jun 2020
    Share Share
    Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105
    Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105

    02 Jun 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/06/02/2042185/0/en/Menlo-Therapeutics-Announces-Positive-Results-from-Phase-2-Trial-of-FCD105-for-the-Treatment-of-Moderate-to-Severe-Acne-Vulgaris.html

    GLOBENEWSWIRE
    02 Jun 2020
    Share Share
    Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam
    Menlo Therapeutics Receives FDA Approval of ZILXI™ (minocycline) topical foam

    29 May 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/menlo-therapeutics-receives-fda-approval-of-zilxi-minocycline-topical-foam-1-5-the-first-topical-minocycline-treatment-for-rosacea-301067795.html

    PRNEWSWIRE
    29 May 2020
    Share Share
    Menlo Therapeutics Announces Covered Status for AMZEEQ®
    Menlo Therapeutics Announces Covered Status for AMZEEQ®

    27 May 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/05/27/2039354/0/en/Menlo-Therapeutics-Announces-Covered-Status-for-AMZEEQ-minocycline-topical-foam-4-on-Additional-Commercial-Formulary.html

    GLOBENEWSWIRE
    27 May 2020
    Share Share
    Menlo & Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™
    Menlo & Cutia Therapeutics Enter into Exclusive License Agreement for AMZEEQ™

    23 Apr 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/04/23/2020865/0/en/Menlo-Therapeutics-and-Cutia-Therapeutics-Enter-into-Exclusive-License-Agreement-for-AMZEEQ-and-Approved-Topical-Minocycline-Products-in-Greater-China.html

    GLOBENEWSWIRE
    23 Apr 2020
    Share Share
    Menlo hit with serlopitant setback
    Menlo hit with serlopitant setback

    07 Apr 2020

    // Selina McKee PHARMATIMES

    http://www.pharmatimes.com/news/menlo_hit_with_serlopitant_setback_1337850

    Selina McKee PHARMATIMES
    07 Apr 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search